依达拉奉对急性脑梗死患者血清炎症因子水平的影响(1)
 |
| 第1页 |
参见附件(1835KB，3页)。
【摘要】 目的 观察依达拉奉对急性脑梗死患者血清炎症因子白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)和超敏C反应蛋白(hs-CRP)水平的影响。方法 选择急性脑梗死患者120例,随机分为依达拉奉组60例和常规治疗组60例, 选择门诊健康体检者60例作为正常对照组。所有脑梗死患者均于入院时、治疗后3 d、7 d、14 d分别抽静脉血3 ml检测血清中IL-6、TNF-α、hs-CRP含量各1次,门诊健康体检者仅测定1次血清IL-6、TNF-α、hs-CRP含量。结果 脑梗死患者血清IL-6、TNF-α及hs-CRP浓度水平较健康体检组明显升高(P<0.01)。依达拉奉组和常规治疗组治疗前血清IL-6、TNF-α及hs-CRP含量测定无明显差异(P>0.05),治疗后依达拉奉组血清IL-6、TNF-α浓度治疗后3 d、7 d和14 d逐步下降,较常规治疗组有显著差异(P<0.01)。依达拉奉组治疗后7 d和14 d血清hs-CRP浓度含量测定明显降低(P<0.05和P<0.01);常规治疗第14天血清hs-CRP浓度才明显降低(P<0.05);两组间治疗第7天和第14天有显著差异(P<0.05)。依达拉奉对于中重度病情患者的血清IL-6、TNF-α、hs-CRP水平的影响比轻度病情患者影响更大。结论 急性脑梗死患者血清IL-6、TNF-α和hs-CRP含量明显增加,依达拉奉能显著降低急性脑梗死患者血清炎症因子IL-6、 TNF-α和hs-CRP的水平,且对病情重者影响更明显。
【关键词】 依达拉奉;脑梗死;; IL-6;TNF-α;hs-CRP
【Abstract】 Objective To study the effects of edaravone on levels of inflammatory factors interleukin -6 (IL-6), tumor necrosis factor -α(TNF-α) and high sensitive C-reactive protein (hs-CRP) in patients with acute cerebral infarction.Methods 120 patients with acute cerebral infarction were randomly divided into edaravone group(n=60)and conventional therapy group(n=60),and 60 cases healthy were selected as the normal control group.Respectively 3 ml venous bloodof all patientswith cerebral infarction were collected at the time of admission, the 3 d, 7 d and 14 d after treatment.Then the serum IL-6, TNF-α and hs-CRP levels of all patients were detected.Results The IL-6, TNF-α and hs-CRP levels in cerebral infarction patients were significantly higher than those in healthy subjects (P<0.01).There were no significant difference (P>0.05)in levels of IL-6, TNF-α and hs-CRP between edaravone group andconventional treatment group before treatment.With the time prolonged,the levels of IL-6, TNF-α in edaravone group were gradually decreased at the 3 d,7 d and 14 d after treatment,and were significantly different compared with conventional treatment group (P<0.01). The hs-CRP levels in edaravone group decreased significantly at the 7 d,14 d after treatment (P<0 ......
您现在查看是摘要介绍页，详见PDF附件(1835KB，3页)。